SARC Clinical Trials: Past and Present

Below is a list of trials conducted by SARC, a brief description of the clinical trial, and whether or not the study is open to enrolling new patients.

STUDY #

TRIAL PHASE

STUDY

DESCRIPTION

TYPE OF

SARCOMA

ACCEPTING NEW PATIENTS**

SARC001

II

Imatinib mesylate (gleevec) in patients with soft tissue and bone sarcomas: a multi-disciplinary trial

Soft tissue and
bone sarcoma

NO

SARC002

III

120-minute infusion gemcitabine v. 90-minute infusion Gemcitabine plus Docetaxel in unresectable soft tissue sarcoma.

Unresectable
soft tissue sarcoma

NO

SARC003

II

Sequential gemcitabine followed by docetaxel for recurrent ewing's sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma

Ewing's,Osteosarcoma and Chondrosarcoma

NO

SARC004

       II

Short course of neoadjuvant gleevec (imatinib mesylate) in dermatofibrosarcoma protuberans

Dermatofibrosarcoma protuberans

NO

SARC005

II

Adjuvant treatment of high risk leiomyosarcoma with gemcitabine/ docetaxel, followed by doxorubicin: a phase II multi-center trial

Uterine leiomyosarcoma

NO

SARC006

II

Neoadjuvant chemo-therapy in sporadic and nurofibromatosis type 1 associated high grade unresectable or metastatic potentially resectable malignant peripheral nerve sheath tumors

Sporadic and neuro- fibromatosis associated with peripheral nerve sheath tumors

NO

SARC007

II

Perifosine in patients with chemo-Insensitive sarcomas

Chemo-insensitive sarcomas

NO

SARC009

II

Dasatinib in advanced sarcoma

Advanced sarcoma

NO

SARC011

II

R1507 IGF1R, a recombinant human monoclonal antibody for the treatment of patients with recurrent or refractory ewing's sarcoma, and other soft tissue sarcomas

Ewing's, Osteosarcoma, synovial, rhabdomyo-sarcoma and others

NO

SARC012

II

AZD0530, a selective src kinase inhibitor, in patients w/recurrent osteosarcoma localized to the lung

Osteosarcoma

YES

SARC016

II

mTOR inhibitor RAD001 (everolimus) in combination with bevacizumab (avastin) in patients with sporadic & neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors

Malignant peripheral nerve sheath tumors

YES

SARC019

III

Dose escalation versus no dose escalation of Imatinib In metastatic GIST patients w/imatinib trough levels less than 1100 nanograms/mL.

Gastro-intestinal stromal tumors

NO

SARC020

IIb/III

Comparing the efficacy of Trabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma

Histologically proven advanced and/or metastatic malignant soft tissue sarcoma intermediate/high grade; some subtypes excluded.

Recruitment

Suspended

SARC021

III

TH-302 in combination with doxorubicin compared to doxorubicin to doxorubicin alone

Soft tissue sarcoma

YES

SARC022

II

OSI-906, an oral tyrosine kinase inhibitor, in patients with gastrointestinal stromal tumors

Advanced wild-type gastrointestinal stromal tumors (GIST)

YES

**When a trial is not accepting new patients, this means the study enrollment has been completed.